1: Lee L, Flach S, Xue H, Arivelu L, Golden L, Kong R, Darpo B. Lack of Concentration-QTc Relationship and Cardiac Risk With Vatiquinone Therapeutic and Supratherapeutic Doses. Clin Pharmacol Drug Dev. 2024 Nov;13(11):1227-1238. doi: 10.1002/cpdd.1476. Epub 2024 Oct 17. PMID: 39415654.
2: Lee L, Okudaira N, Murase K, Kong R, Jones HM. Determination of Vatiquinone Drug-Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation. J Clin Pharmacol. 2024 Sep 23. doi: 10.1002/jcph.6133. Epub ahead of print. PMID: 39308341.
3: Lee L, Thoolen M, Ma J, Kaushik D, Golden L, Kong R. Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone. Clin Pharmacol Drug Dev. 2024 Dec;13(12):1283-1290. doi: 10.1002/cpdd.1461. Epub 2024 Aug 12. PMID: 39133029; PMCID: PMC11609057.
4: Chang KH, Chen CM. The Role of NRF2 in Trinucleotide Repeat Expansion Disorders. Antioxidants (Basel). 2024 May 26;13(6):649. doi: 10.3390/antiox13060649. PMID: 38929088; PMCID: PMC11200942.
5: Kayser EB, Chen Y, Mulholland M, Truong V, James K, Hanaford A, Johnson S. Evaluating the efficacy of vatiquinone in preclinical models of mitochondrial disease. Res Sq [Preprint]. 2024 Jun 3:rs.3.rs-4202689. doi: 10.21203/rs.3.rs-4202689/v1. PMID: 38883711; PMCID: PMC11177993.
6: Ma J, Lee L, Yao B, Giannousis P, Thoolen M, Ye Q, Golden L, Klein M, Kong R. Absorption, distribution, metabolism and excretion of 14C-vatiquinone in rats, dogs, and human subjects. Xenobiotica. 2023 May;53(5):396-411. doi: 10.1080/00498254.2023.2245459. Epub 2023 Aug 18. PMID: 37552765.
7: Cores Á, Carmona-Zafra N, Clerigué J, Villacampa M, Menéndez JC. Quinones as Neuroprotective Agents. Antioxidants (Basel). 2023 Jul 20;12(7):1464. doi: 10.3390/antiox12071464. PMID: 37508002; PMCID: PMC10376830.
8: Jain P, Badgujar L, Spoorendonk J, Buesch K. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review. Ther Adv Rare Dis. 2022 Nov 29;3:26330040221139872. doi: 10.1177/26330040221139872. PMID: 37180421; PMCID: PMC10032438.
9: Lee L, Murase K, Ma J, Thoolen M. Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate. Clin Pharmacol Drug Dev. 2023 Mar;12(3):279-286. doi: 10.1002/cpdd.1199. Epub 2022 Dec 7. PMID: 36478438.
10: Murase K, Lee L, Ma J, Barrett R, Thoolen M. Evaluation of vatiquinone drug- drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects. Eur J Clin Pharmacol. 2022 Nov;78(11):1823-1831. doi: 10.1007/s00228-022-03393-0. Epub 2022 Sep 27. PMID: 36166059.
11: Khan H, Kaur Grewal A, Gurjeet Singh T. Mitochondrial dynamics related neurovascular approaches in cerebral ischemic injury. Mitochondrion. 2022 Sep;66:54-66. doi: 10.1016/j.mito.2022.08.001. Epub 2022 Aug 5. PMID: 35940452.
12: Kahn-Kirby AH, Amagata A, Maeder CI, Mei JJ, Sideris S, Kosaka Y, Hinman A, Malone SA, Bruegger JJ, Wang L, Kim V, Shrader WD, Hoff KG, Latham JC, Ashley EA, Wheeler MT, Bertini E, Carrozzo R, Martinelli D, Dionisi-Vici C, Chapman KA, Enns GM, Gahl W, Wolfe L, Saneto RP, Johnson SC, Trimmer JK, Klein MB, Holst CR. Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS One. 2019 Mar 28;14(3):e0214250. doi: 10.1371/journal.pone.0214250. PMID: 30921410; PMCID: PMC6438538.
13: Finsterer J, Zarrouk-Mahjoub S. Is vatiquinone truly beneficial for Leigh syndrome? Brain Dev. 2018 May;40(5):443. doi: 10.1016/j.braindev.2017.10.002. Epub 2017 Oct 18. PMID: 29054334.